{"id":48567,"date":"2026-07-31T02:57:00","date_gmt":"2026-07-31T00:57:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=5fd0a0bda1108cf3da3eb52f91fccb6b"},"modified":"2026-07-31T02:57:00","modified_gmt":"2026-07-31T00:57:00","slug":"acadia-pharmaceuticals-to-participate-in-the-canaccord-genuity-46th-annual-growth-conference","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=48567","title":{"rendered":"Acadia Pharmaceuticals to Participate in the Canaccord Genuity 46th Annual Growth Conference"},"content":{"rendered":"

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at Canaccord Genuity 46th<\/sup> Annual Growth Conference on Wednesday, August 12, 2026 at 1:30 p.m. Eastern Time.<\/p><\/a><\/a>

\nLive webcasts will be accessible on the company\u2019s website, acadia.com<\/a>, under the investors section and an archived recording will be available on the website for approximately one month following each presentation.<\/p>

\nAbout Acadia Pharmaceuticals<\/i><\/p>

\nAcadia is committed to turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world. Our commercial portfolio includes the first and only FDA-approved treatments for Parkinson\u2019s disease psychosis and Rett syndrome. We are developing the next wave of therapeutic advancements with a robust and diverse pipeline that includes mid- to late-stage programs in Alzheimer\u2019s disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. At Acadia, we\u2019re here to be their difference. For more information, visit us at acadia.com <\/a>and follow us on LinkedIn<\/a> and X<\/a>.<\/p> Contacts<\/b>

\nInvestor Contact:<\/i>Acadia Pharmaceuticals Inc.\nAl Kildani\n(858) 261-2872\nir@acadia-pharm.com<\/a><\/p>

\nAcadia Pharmaceuticals Inc.\nJessica Tieszen\n(858) 261-2950\nir@acadia-pharm.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"

SAN DIEGO–(BUSINESS WIRE)–Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026 at 1:30 p.m. Eastern Time.
\nLive webcasts…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-48567","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/48567","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=48567"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/48567\/revisions"}],"predecessor-version":[{"id":48568,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/48567\/revisions\/48568"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=48567"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=48567"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=48567"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}